MRG004A Antibody

Cat. No.: HY-P991989: Data Sheet
FAQs
Technical Support

MRG004A Antibody (HuSC1-39) is a monoclonal antibody inhibitor targeting tissue factor (TF). MRG004A Antibody can be used to synthesize the antibody-drug conjugate (ADC) MRG004A. MRG004A Antibody can be used to research related to cancer.

For research use only. We do not sell to patients.

MRG004A Antibody Chemical Structure

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Species Reactivity

Human

In Vitro

MRG004A Antibody activates the STING pathway via proteasome-dependent degradation of TREX1, leading to cytosolic micronuclei accumulation, increased STING pathway phosphorylation, and STING-dependent induction of CCL5 and CXCL10 mRNA in HPAF-II, BxPC3, MDA-231, and HCC1806 cells^[1].
MRG004A Antibody (15 μg/mL; 24 h for cytokine secretion, 48 h for viability) increases CXCL10 and IFN^−γ secretion and reduces tumor cell viability in HPAF-II, BxPC3, or MDA-231 cells co-cultured with PBMCs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	human PDAC HPAF-II, BxPC3 cells, human TNBC MDA-231 cells, PBMCs
Concentration:	15 μg/mL (cytokine secretion); 15 μg/mL (tumor cell viability)
Incubation Time:	24 h (cytokine secretion); 48 h (tumor cell viability)
Result:	Increased secretion of CXCL10 and IFN-γ. Reduced tumor cell viability.

In Vivo

MRG004A Antibody (HuSC1-3) (10 mg/kg; i.v.; 2 doses on days 14 and 18 post-implantation) profoundly inhibits orthotopic HPAF-II pancreatic ductal adenocarcinoma growth in nude mice, activates the STING innate immune pathway, reduces pro-tumor signaling, increases immune effector cell infiltration, and depletes TREX1 protein levels^[1].
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous BxPC3 pancreatic ductal adenocarcinoma growth in nude mice, activates the STING innate immune pathway, reduces pro-tumor signaling, and depletes TREX1 protein levels^[1].
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous HPAF-II pancreatic ductal adenocarcinoma growth in nude mice, activates the STING innate immune pathway, reduces pro-tumor signaling, and depletes TREX1 protein levels^[1].
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous HCC1806 triple-negative breast cancer growth in nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice^[1]
Dosage:	10 mg/kg
Administration:	i.v.
Result:	Inhibited tumor growth. Reduced TF, P-ERK, and P-AKT relative intensity in tumor sections. Increased P-STING and P-TBK1 relative intensity in tumor sections. Nearly eliminated TREX1 protein staining in tumor tissue.\nInhibited tumor growth. Reduced TF, P-ERK, and P-AKT relative intensity in tumor sections. Increased P-STING and P-TBK1 relative intensity in tumor sections. Nearly eliminated TREX1 protein staining in tumor tissue.

Animal Model:	Nude mice^[1]
Dosage:	10 mg/kg
Administration:	i.v.
Result:	Inhibited tumor growth.

Gene ID

2152 [NCBI]

Accession

P13726

Target

F3/Factor III/Tissue Factor/CD142

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

SMILES

[MRG004A Antibody]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Xue Y, et al. Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma. Oncogene. 2025;44(11):739-752. [Content Brief]